Search results for "Ejection fraction"

showing 10 items of 378 documents

Clinical Study of Patients with Heart Failure under treatment with Ozone Therapy.

2018

Heart failure (HF) is framed in one of the types of cardiovascular diseases; it consists of an acute and chronic form. The disease can evolve slowly from asymptomatic left ventricular dysfunction, to a state of severe disability, presenting a wide prevalence in the population around 10% in people over 70 years old. More than three-quarters of the deaths from this pathology normally occur in low or middle-income countries. Angola is not exempt from this health problem be observed in a relatively young people, bringing disability and death at an early stage of life. Scientific advances and innovative treatments for the control and prevention of the disease continue to be insufficient.
 T…

education.field_of_studymedicine.medical_specialtyEjection fractionbusiness.industryPopulationDisease:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOzone therapyAsymptomaticAutohemotherapyHeart failureInternal medicineUNESCO::CIENCIAS MÉDICASmedicineCardiologyStage (cooking)medicine.symptomeducationbusinessJournal of Ozone Therapy
researchProduct

Protective Effects of a Discontinuous Treatment with Alpha-Lipoic Acid in Obesity-Related Heart Failure with Preserved Ejection Fraction, in Rats

2020

Obesity induces hemodynamic and humoral changes that are associated with functional and structural cardiac remodeling, which ultimately result in the development of heart failure (HF) with preserved ejection fraction (HFpEF). In recent years, pharmacological studies in patients with HFpEF were mostly unsatisfactory. In these conditions, alternative new therapeutic approaches are necessary. The aim of our study was (1) to assess the effects of obesity on heart function in an experimental model and (2) to evaluate the efficacy of an alpha-lipoic acid (ALA) antioxidant treatment. Sprague-Dawley rats (7 weeks old) were either included in the control group (n = 6) or subjected to abdominal aorti…

heart failure with preserved ejection fraction0301 basic medicineobesitymedicine.medical_specialtyPhysiologymedicine.drug_classClinical BiochemistryDiastoleHemodynamics030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineNatriuretic peptideoxidative stressMolecular BiologyEjection fractionAdiponectinbusiness.industryalpha-lipoic acidlcsh:RM1-950Cell Biologymedicine.diseaselcsh:Therapeutics. Pharmacologyantioxidants030104 developmental biologyEndocrinologyHeart failurebusinessHeart failure with preserved ejection fractionOxidative stressAntioxidants
researchProduct

Sex-Specific Relationship Between Parathyroid Hormone and Platelet Indices in Phenotypes of Heart Failure—Results From the MyoVasc Study

2021

Background: Heart failure (HF) is a multifactorial syndrome with pathophysiological complexities still not fully understood. Higher mean platelet volume (MPV), a potential marker of platelet activation, and high concentrations of parathyroid hormone (PTH) have been implicated in the pathogenesis of HF.Aim: This study aims to investigate sex-specifically the association between PTH concentrations and platelet indices in phenotypes of HF.Methods and Results: PTH and platelet indices (MPV and platelet count) were available in 1,896 participants from the MyoVasc study in Mainz, Germany. Multivariable linear regression models, adjusted for age, sex, season, vitamin D status, cardiovascular risk …

heart failure with preserved ejection fractionBIOMARKERmedicine.medical_specialtyPATHOPHYSIOLOGYheart failureParathyroid hormoneCardiovascular Medicine030204 cardiovascular system & hematologyMPVDISEASE03 medical and health sciences0302 clinical medicineInternal medicineMANAGEMENTVitamin D and neurologymedicineDiseases of the circulatory (Cardiovascular) systemparathyroid hormoneheart failure with reduced ejection fractionPlatelet030212 general & internal medicinePlatelet activationMean platelet volumeVITAMIN-DOriginal ResearchRISKEjection fractionbusiness.industryMORTALITYplatelet countmedicine.diseaseDYSFUNCTIONEndocrinologyRC666-701Heart failureCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessFrontiers in Cardiovascular Medicine
researchProduct

Entrenamiento de la musculatura inspiratoria y la electroestimulación muscular funcional en el tratamiento de la insuficiencia cardiaca con función s…

2019

SEC 2017: Congreso de las Enfermedades Cardiovasculares Introducción y objetivos No se dispone de tratamientos farmacológicos que demuestren reducir la morbimortalidad asociada en pacientes con insuficiencia cardiaca y función sistólica conservada (IC-FEc). El objetivo del presente estudio fue evaluar si en pacientes con IC-FEc, el entrenamiento de la musculatura inspiratoria (EMI), la electroestimulación muscular funcional (EMF) o la combinación de ambas (EMI + EMF) puede mejorar la capacidad funcional, calidad de vida, parámetros de disfunción diastólica o biomarcadores a las 12 y 24 semanas. Métodos Un total de 61 pacientes estables con IC-FEc (clase funcional de la New York Heart Associ…

heart failure with preserved ejection fractioncapacidad funcionalbusiness.industry030204 cardiovascular system & hematologyinsuficiencia cardiaca con función sistólica conservadaexercise capacity03 medical and health sciences0302 clinical medicinequality of lifecalidad de vidaMedicinephysical therapyCardiology and Cardiovascular MedicinebusinessHumanitiesterapia físicaRevista Española de Cardiología
researchProduct

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach.

2020

International audience; To better understand heart failure with preserved ejection fraction (HFpEF), we need to better characterize the transition from asymptomatic pre-HFpEF to symptomatic HFpEF. The current emphasis on left ventricular diastolic dysfunction must be redirected to microvascular inflammation and endothelial dysfunction that leads to cardiomyocyte remodeling and enhanced interstitial collagen deposition. A pre-HFpEF patient lacks signs or symptoms of heart failure (HF), has preserved left ventricular ejection fraction (LVEF) with incipient structural changes similar to HFpEF, and possesses elevated biomarkers of cardiac dysfunction. The transition from pre-HFpEF to symptomati…

heart failure with preserved ejection fractionmedicine.medical_specialtylcsh:MedicineReviewCardiorenal syndromeright ventricle030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systempulmonary arterymedicine.arteryInternal medicineMedicine030212 general & internal medicineEjection fractionbusiness.industrylcsh:Rrenal functionGeneral Medicinemedicine.diseasePulmonary hypertension[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthmedicine.anatomical_structureinflammationVentricleHeart failurePulmonary arteryCardiologycardiovascular systemmedicine.symptomHeart failure with preserved ejection fractionbusinessatrial failure heart failure with preserved ejection fraction inflammation pulmonary artery renal function right ventricleatrial failure
researchProduct

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction

2020

Right ventricular dysfunction (RVD) parameters are increasingly important features in heart failure with preserved ejection fraction (HFpEF). We sought to evaluate the prognostic impact of a progressive RVD staging system by combining the tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (TAPSE/PASP) ratio with functional tricuspid regurgitation (TR) severity. We prospectively included 1355 consecutive HFpEF patients discharged for acute heart failure (HF). Of them, in 471 (34.7%) patients, PASP could not be accurately measured, leaving the final sample size to be 884 patients. Patients were categorized as Stage 1: TAPSE/PASP &ge

heart failure with preserved ejection fractionmedicine.medical_specialtylcsh:Medicinerisk stratification030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicine.arterymedicine030212 general & internal medicineStage (cooking)right ventricularStaging systemRisk stratificationRight ventricularbusiness.industryMortality ratelcsh:RGeneral Medicinemedicine.diseaseBlood pressureHeart failure with preserved ejection fractionHeart failurePulmonary arteryRisk stratificationCardiologybusinessHeart failure with preserved ejection fraction
researchProduct

0134 : Atrial fibrillation is associated with a marker of endothelial function and oxidative stress in patients with acute myocardial infarction

2016

Background Atrial fibrillation (AF), whether silent or symptomatic, is a frequent and severe complication of acute myocardial infarction (AMI). Asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, is a risk factor for endothelial dysfunction. We addressed the relationship between ADMA plasma levels and AF occurrence in AMI. Methods 273 patients hospitalized for AMI were included. Continuous electrocardiographic monitoring (CEM) e48 hours was recorded and ADMA was measured by High Performance Liquid Chromatography on admission blood sample. Results The incidence of silent and symptomatic AF was 39(14%) and 29 (11%), respectively. AF patients were markedly older than patients wit…

medicine.medical_specialty030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHeart ratemedicine030212 general & internal medicineMyocardial infarctionEndothelial dysfunctionRisk factorComputingMilieux_MISCELLANEOUSEjection fractionbusiness.industryIncidence (epidemiology)Atrial fibrillationEndothelial function[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseAtrial fibrillation3. Good healthMyocardial infarctionchemistryCardiologyCardiology and Cardiovascular MedicineAsymmetric dimethylargininebusiness
researchProduct

0127: Atrial fibrillation is associated with a marker of endothelial function and oxidative stress in patients with acute myocardial infarction

2016

Background Atrial fibrillation (AF), whether silent or symptomatic, is a frequent and severe complication of acute myocardial infarction (AMI). Asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, is a risk factor for endothelial dysfunction. We addressed the relationship between ADMA plasma levels and AF occurrence in AMI. Methods 273 patients hospitalized for AMI were included. Continuous electrocardiographic monitoring (CEM) ≥48 hours was recorded and ADMA was measured by High Performance Liquid Chromatography on admission blood sample. Results The incidence of silent and symptomatic AF was 39(14%) and 29 (11%), respectively. AF patients were markedly older than patients wit…

medicine.medical_specialty030204 cardiovascular system & hematologyPathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHeart rateMedicine030212 general & internal medicineMyocardial infarctionRisk factorEndothelial dysfunctionComputingMilieux_MISCELLANEOUSEjection fractionbusiness.industryAtrial fibrillationEndothelial function[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseAtrial fibrillation3. Good healthMyocardial infarctionchemistryCardiologyCardiology and Cardiovascular MedicinebusinessAsymmetric dimethylarginine
researchProduct

Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology

2020

Self-care is essential in the long-term management of chronic heart failure. Heart failure guidelines stress the importance of patient education on treatment adherence, lifestyle changes, symptom monitoring and adequate response to possible deterioration. Self-care is related to medical and person-centred outcomes in patients with heart failure such as better quality of life as well as lower mortality and readmission rates. Although guidelines give general direction for self-care advice, health care professionals working with patients with heart failure need more specific recommendations. The aim of the management recommendations in this paper is to provide practical advice for health profe…

medicine.medical_specialty2013 ACCF/AHA GUIDELINElifestyleTreatment adherenceCardiologyheart failure/dk/atira/pure/subjectarea/asjc/2700/2705Heart failureNursing030204 cardiovascular system & hematologyAMERICAN-COLLEGEEXERCISE CAPACITYpatient education03 medical and health sciencesAIR-TRAVEL0302 clinical medicineQuality of life (healthcare)MEDICATIONQUALITY-OF-LIFEHealth careself-caremedicineHumansIn patientIntensive care medicineVENTRICULAR DYSFUNCTIONbusiness.industrySymptom managementOmvårdnadSelf‐careDisease ManagementPatient educationmedicine.diseaseLifestyle3. Good healthSelf CareHeart failureChronic DiseaseSelf careQuality of LifeCARDIOVASCULAR-DISEASESSelf-care; Heart failure; Lifestyle; Patient educationPosition PaperSelf-carebusinessCardiology and Cardiovascular MedicineREDUCED EJECTION FRACTIONPatient educationTASK-FORCE
researchProduct

Empagliflozin in heart failure with preserved ejection fraction: decoding its molecular mechanism of action using artificial intelligence

2021

Abstract   Rationale The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial intelligence (AI) to characterize the mechanism of action of empagliflozin in HFpEF at the molecular level. Methods We retrieved information regarding HFpEF pathophysiological motifs and differentially expressed genes/proteins, together with empagliflozin target information and bioflags, from specialized publicly available databases. Artificial neural networks and deep learning AI were used to model the molecular effec…

medicine.medical_specialtyAction (philosophy)business.industryInternal medicineEmpagliflozinmedicineMolecular mechanismCardiologyCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionDecoding methodsEuropean Heart Journal
researchProduct